Don’t reinvent the wheel — adapt it. Locate before you correct, because where a failure appears isn’t necessarily where it gets fixed.
- Closing The Gap Between Modeling And GMP Predictive Control
- Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
- What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI
- How Is Your Glass Supplier Adapting To Europe's Energy Crisis?
- Can Peptide Mapping Predict Intact Antibody PTM Distributions?
- The EU Overhauls Pharma Laws: What You Need To Know
- An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
GUEST COLUMNISTS
-
Closing The Gap Between Modeling And GMP Predictive Control
Predictive control offers opportunities to improve process consistency, reduce variability, and respond to changing manufacturing conditions before they cause deviations.
-
Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
Determining whether a drug manufacturing environment is stable, drifting, or developing a recurring loss-of-control signal requires integrated trend evaluation.
-
What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI
The European Commission and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consulted on draft Annex 22, Artificial Intelligence. Here's what you should know.
-
How Is Your Glass Supplier Adapting To Europe's Energy Crisis?
Europe's glass manufacturers, including those making pharmaceutical lab glassware, have experienced a series of energy shocks. Many have adopted sustainability practices.
-
Can Peptide Mapping Predict Intact Antibody PTM Distributions?
Peptide mapping quantifies modification at individual sites, but the same site-level results can correspond to different distributions across intact molecules.
-
The EU Overhauls Pharma Laws: What You Need To Know
On Sept. 18, the Council of the EU published the almost-final text of a major overhaul of the EU pharmaceutical laws. The final binding text is expected to be published very soon.
-
An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
FDA’s real-time CRL releases face legal and operational hurdles. Could AI-assisted redaction make transparency faster and more consistent?
BIOSIMILAR WHITE PAPERS
-
Economic Advantage Of Robotic Gloveless Pharmaceutical Isolators
Are robotic gloveless isolators the key to smarter, safer, scalable solutions? Discover how they can revolutionize aseptic filling by reducing contamination, minimizing waste, and enhancing manufacturing flexibility.
-
Why Biopharma Breakthroughs Aren't Moving The Market10/20/2025
Biopharma is innovating fast but falling short commercially. Reveal key ecosystem gaps and five strategic actions to help strengthen resilience, accelerate performance, and futureproof organizations.
-
Biopharma Supply, Reimagined: Regional, Resilient Manufacturing4/1/2026
Persistent disruption is redefining biopharma supply chains. Explore how regional manufacturing, integrated risk management, and closer collaboration help build resilience and improve agility.
-
Process Analytical Technology In The ADC Bioconjugation Process4/23/2025
Integrating Process Analytical Technology into validated GMP processes is complex and costly, which requires thorough validation of equipment and cleaning methods. Explore more about PAT's role in ADC production.
-
Process Intensification And Other Ways To Adapt To Changing Needs7/20/2026
As biologics manufacturing evolves, gain insight into why productivity depends on smarter investments, flexible production strategies, and supplier support that can address shifting modalities.
-
ADC Development Grows More Complex — SPR Insights Bring Clarity4/14/2026
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
BIOSIMILAR APP NOTES & CASE STUDIES
- Discover A System That Can Be Used With Various Cell Culture Media
- Packing MabSelect™ And MabSelect SuRe™ Resins Using Verified Methods
- Seed Train Intensification Using High Cell Density Cryopreservation
- Assessing Particle Generation In A Single-Use Mixing System
- Microbial Integrity Of Sampling Systems After Multiple Actuations
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Biocon Gets U.S. FDA Approval For Pebrilzo (pertuzumab-qcay) Injection, A Biosimilar To Perjeta, Expanding Its Oncology Portfolio
- Celltrion to Present New Analyses of OMLYCLO® (omalizumab-igec) In Chronic Spontaneous Urticaria At ACAAI 2026
- Lupin Announces European Launch Of Biosimilar Ranibizumab
- Sandoz launches Ranluspec (ranibizumab) In Europe, Providing An Affordable Treatment Option For Patients With Retinal Diseases
- Henlius Presents New Studies At ISPOR Europe 2026 To Advance Treatment Value Assessment And Global Access
- AEON Biopharma Submits IND For Comparative Pharmacodynamic Study Of ABP-450
- New Biosimilar For Patients With Certain HER2-Positive Breast Cancer Is Approved By Anvisa
- GlycoNex Announces Japanese Regulatory Submission For Denosumab Biosimilar SPD8
NEWSLETTER ARCHIVE
- 11.12.26 -- 5 Steps To Achieving Your Biosimilar Milestones On Time
- 11.05.26 -- 7 Decisions To Make Before MES Configuration
- 10.29.26 -- How Indian Biosimilar Companies Are Poised To Succeed
- 10.27.26 -- Reduce Bioprocessing Supply Risk With Manufacturing Closer To You
- 10.22.26 -- Reduce risk. Move Annex 1 forward.
